Dupix­ent scores speedy re­view for rhi­nos­i­nusi­tis with nasal polyps; Af­ter trans­plant, third pa­tient is HIV-free for 3 months

Re­gen­eron $REGN and Sanofi’s $SNY mon­o­clon­al an­ti­body Dupix­ent — al­ready ap­proved for eczema and asth­ma — is in line for an­oth­er ap­proval. The FDA has grant­ed the drug — which made $922 mil­lion in net sales last year — pri­or­i­ty re­view for pa­tients with se­vere chron­ic rhi­nos­i­nusi­tis with nasal polyps, who of­ten see their dis­ease re­turn de­spite surgery and/or sys­temic cor­ti­cos­teroids. The US agency is ex­pect­ed to make its de­ci­sion by June 26. 

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.